Statistiche di base
| LEI | 213800NTOH3FK3WER551 |
| CIK | 1811115 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Renalytix Plc - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| September 4, 2025 |
Exhibit (a)(ii) DEPOSIT AGREEMENT by and among Renalytix AI plc and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of July 21, 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 1 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 1 Section 1.4 |
|
| September 4, 2025 |
As filed with the Securities and Exchange Commission on September 4, 2025 Registration No. |
|
| September 4, 2025 |
Exhibit (a)(i) RENALYTIX plc AND CITIBANK, N.A., As Depositary, AND ALL HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED AND OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF JULY 21, 2020 Amendment No. 1 to Deposit Agreement Dated as of [●], 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions 1 SECTION 1.02 Effective Date 2 ARTICLE II AME |
|
| July 30, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration Statement on Form F-6 Registration No. |
|
| July 30, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39387 Renalytix plc (Exact name of registrant as specified in its charte |
|
| July 29, 2025 |
As filed with the Securities and Exchange Commission on July 29, 2025 As filed with the Securities and Exchange Commission on July 29, 2025 Registration No. |
|
| July 29, 2025 |
As filed with the Securities and Exchange Commission on July 29, 2025 As filed with the Securities and Exchange Commission on July 29, 2025 Registration No. |
|
| July 29, 2025 |
As filed with the Securities and Exchange Commission on July 29, 2025 As filed with the Securities and Exchange Commission on July 29, 2025 Registration No. |
|
| July 29, 2025 |
As filed with the Securities and Exchange Commission on July 29, 2025 As filed with the Securities and Exchange Commission on July 29, 2025 Registration No. |
|
| July 29, 2025 |
As filed with the Securities and Exchange Commission on July 29, 2025 As filed with the Securities and Exchange Commission on July 29, 2025 Registration No. |
|
| July 25, 2025 |
Registration No. 333-274732 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Renalytix plc (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 2 Leman Street |
|
| July 25, 2025 |
Registration No. 333-248741 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Renalytix plc (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 2 Leman Street |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| December 20, 2024 |
Renalytix plc (“Renalytix” or the “Company”) Result of AGM Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Result of AGM LONDON and NEW YORK, 19 December 2024 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which is commercialising the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment for chronic kidney disease, announces that at the Annual General Meeting (“AGM”) held earlier today, all resolutions wer |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction (Commission File Number) |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39387 Renaly |
|
| November 14, 2024 |
SC 13G/A 1 tm2428264d6sc13ga.htm SC 13G/A CUSIP No: 75973T101 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Renalytix plc (Name of Issuer) Ordinary Shares, £0.0025 nominal value per share (Title of Cl |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 7, 2024 |
SC 13D/A 1 tm2427702d1sc13da.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* RENALYTIX PLC (Name of Issuer) Ordinary Shares, nominal value £0.0025 per share Underlying American Depositary Shares (Title of Class of Securities) 75973T101 (American Depositary Shares) (CUSIP Number) Pet |
|
| November 6, 2024 |
Renalytix plc (“Renalytix” or the “Company”) Result of General Meeting Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Result of General Meeting LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, at the General Meeting (“GM”) |
|
| November 6, 2024 |
Renalytix plc (“Renalytix” or the “Company”) Directorate Change Exhibit 99.2 Renalytix plc (“Renalytix” or the “Company”) Directorate Change LONDON and NEW YORK, 31 October 2024 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that Dan Levangie, Non-Executive Director |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction (Commission File Number) |
|
| November 5, 2024 |
SC 13D/A 1 sc13da2.htm SCHEDULE 13D, AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.2)* RENALYTIX PLC (Name of Issuer) ORDINARY SHARES (Including Ordinary Shares Underlying American Depository Shares) (Title of Class of Securities) 75973T101 (American Depository Shares) (CUSIP Number) Moun |
|
| October 11, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-39387 Renalytix plc The Nasdaq Stock Market LLC (Exact name of registrant as specified in its charter, and name of Exchange where security is listed and/or registered) 2 Leman Stre |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* RENALYTIX PLC (Name of Issuer) Ordinary Shares, nominal value £0.0025 per share Underlying American Depositary Shares (Title of Class of Securities) 75973T101 (American Depositary Shares) (CUSIP Number) Peter Trapani Chief Financial Officer Jefferson Riv |
|
| October 1, 2024 |
Form of Subscription Agreement Exhibit 10.2 FORM OF SUBSCRIPTION LETTER TO: Renalytix PLC (the “Company”) 2 Leman Street, London United Kingdom E1W 9US FAO: FROM: September 2024 Re: Placing (the “Placing”) of new ordinary shares (the “Shares”) of the Company Please note all definitions used herein shall have the same meaning as defined in the Placing Announcement, unless expressed otherwise. Dear all: We (the “Subscriber” o |
|
| October 1, 2024 |
Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Update on financial results for the fiscal year ended 30 June 2024 LONDON and NEW YORK, 30 September, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, w |
|
| October 1, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| October 1, 2024 |
Exhibit 99.3 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (TOGETHER THIS “ANNOUNCEMENT”) IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER P |
|
| October 1, 2024 |
Placing Agreement dated October 1, 2024 Exhibit 10.1 Dated 1 October 2024 RENALYTIX PLC as the Company AND OBERON CAPITAL (A TRADING NAME OF OBERON INVESTMENTS LIMITED) as Broker PLACING AGREEMENT in respect of a Placing of Ordinary Shares to raise gross proceeds of approximately £10 million in two tranches TABLE OF CONTENTS Page 1. DEFINITIONS AND INTERPRETATION 4 2. CONDITIONS 12 3. DELIVERY OF DOCUMENTS 15 4. APPLICATIONS FOR ADMISSI |
|
| October 1, 2024 |
Exhibit 99.2 THIS ANNOUNCEMENT, INCLUDING THE APPENDICES TO THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO |
|
| September 30, 2024 |
Subsidiaries of the registrant EX-21.1 2 rnlx-ex211.htm EX-21.1 EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction Renalytix AI, Inc. United States Renalytix AI Limited Ireland |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39387 Renalytix plc (Exac |
|
| August 27, 2024 |
Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Nasdaq Grants Listing Extension Renalytix’s American Depositary Shares (“ADSs”) will Continue Trading on The Nasdaq Capital Market Effective at the Open of Trading on August 27, 2024 LONDON and NEW YORK, 27 August 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on opt |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| July 15, 2024 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| July 15, 2024 |
Renalytix plc (“Renalytix” or the “Company”) Issue of Shares and Rule 2.9 Announcement Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Issue of Shares and Rule 2.9 Announcement LONDON and NEW YORK – July 15, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), announces the repayment of $1.06 million of the principal amount of the Company’s convertible bond and the interest for the period, further details of which were announced on 31 March 2022. The repayment is being made th |
|
| June 28, 2024 |
Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-279966 PROSPECTUS 26,815,841 Ordinary Shares This prospectus relates to the resale by the selling securityholders identified in this prospectus, or the selling securityholders, of up to 26,815,841 ordinary shares of Renalytix plc, or the Company. We are not selling any securities and will not receive any proceeds from the sale of the |
|
| June 26, 2024 |
As filed with the Securities and Exchange Commission on June 25, 2024 S-3/A Table of Contents As filed with the Securities and Exchange Commission on June 25, 2024 Registration No. |
|
| June 26, 2024 |
2 Leman Street London E1W 9US United Kingdom 2 Leman Street London E1W 9US United Kingdom June 26, 2024 Via Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jane Park Re: Renalytix plc Registration Statement on Form S-3 File No. 333-279966 Acceleration Request Requested Date: June 28, 2024 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Pursuant to R |
|
| June 25, 2024 |
Exhibit 16.1 June 24, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated June 18, 2024, of Renalytix plc and are in agreement with the statements contained in the first, second, third and fourth paragraphs under the heading (b) Previous Independent Registered Public Accounting Firm on page 3 therein. We have no ba |
|
| June 25, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incor |
|
| June 24, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| June 24, 2024 |
Exhibit 16.1 June 24, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated June 19, 2024, of Renalytix plc and are in agreement with the statements contained in the first, second, third and fourth paragraphs under the heading (b) Previous Independent Registered Public Accounting Firm on page 3 therein. We have no ba |
|
| June 24, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| June 17, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| June 17, 2024 |
Exhibit 99.1 This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. Renalytix plc |
|
| June 14, 2024 |
As filed with the Securities and Exchange Commission on June 14, 2024 Table of Contents As filed with the Securities and Exchange Commission on June 14, 2024 Registration No. |
|
| June 12, 2024 |
Consulting Agreement, dated as of June 7, 2024, between Renalytix AI, Inc. and Joel R. Jung Exhibit 10.1 Consulting Services Agreement This Consulting Services Agreement (“Agreement”) is made and entered into as of June 7th, 2024 by and between Renalytix AI, Inc. (the “Company”), and the undersigned individual (“Consultant”). The Company desires to retain Consultant as an independent contractor to perform consulting services for the Company and Consultant is willing to perform such servi |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| June 5, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Renalytix plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity American Depositary Shares (ADSs) 457(c) 13,407,921 $0. |
|
| June 5, 2024 |
As filed with the Securities and Exchange Commission on June 5, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 5, 2024 Registration No. |
|
| May 28, 2024 |
Renalytix plc (“Renalytix” or the “Company”) Management Change Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Management Change LONDON and SALT LAKE CITY – 28 May 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that O. James Sterling will step down from his role as Chief Financial Officer of the Company as of 24 May 2024 and will remain at the Company until 10 June 2024. The Board has appointed Joel R. Jung as Interim Chief Financial Offi |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2024 |
At The Market Offering Agreement by and between Renalytix plc and H.C. Wainwright & Co. LLC Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT May 15, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Renalytix plc, a public limited company incorporated under the laws of England and Wales (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used i |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2024 |
Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024 LONDON and NEW YORK, May 15, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39387 Renalytix |
|
| May 15, 2024 |
Up to $15,000,000 American Depositary Shares Representing Ordinary Shares Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-274733 PROSPECTUS SUPPLEMENT To Prospectus, dated October 6, 2023 Up to $15,000,000 American Depositary Shares Representing Ordinary Shares We have entered into an At The Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, relating to the offer and sale of our American Depositary |
|
| May 8, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-278765 PROSPECTUS 19,986,031 Ordinary Shares This prospectus relates to the resale by the selling securityholders identified in this prospectus, or the selling securityholders, of up to 19,986,031 ordinary shares of Renalytix plc, or the Company. We are not selling any securities and will not receive any proceeds from the sale |
|
| April 26, 2024 |
Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Allotment and issue of the Second Tranche Placing Shares Rule 2.9 Announcement LONDON and SALT LAKE CITY – 25 April 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) confirms that the Second Tranche Placing Shares of 26,815,841 ordinary shares of £0.0025 each (the “Ordinary Shares”) were issued yesterday, on the 24 April 2024. An application |
|
| April 26, 2024 |
SC 13D/A 1 sc13da-1.htm SCHEDULE 13D/A - AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* RENALYTIX PLC (Name of Issuer) ORDINARY SHARES (Including Ordinary Shares Underlying American Depository Shares) (Title of Class of Securities) 75973T101 (American Depository Shares) (CUSIP Number |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| April 25, 2024 |
2 Leman Street London E1W 9US United Kingdom 2 Leman Street London E1W 9US United Kingdom April 25, 2024 Via Edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jessica Ansart Re: Renalytix plc Registration Statement on Form S-3 Filed on April 17, 2024 File No. 333-278765 Acceleration Request Requested Date: April 29, 2024 Requested Time: 4:00 p.m. Eastern Time Ladi |
|
| April 23, 2024 |
Separation Agreement, dated April 17, 2024, by and between the Company and Tom McLain Exhibit 10.2 April 17, 2024 Thomas McLain Dear Tom: As we have discussed, your employment with Renalytix AI, Inc. (the “Company”) is coming to an end, effective as of April 30, 2024 (the “Separation Date”). The purpose of this letter agreement (this “Agreement”) is to confirm the terms concerning your transition from employment. Capitalized terms not defined in this Agreement will have the respect |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| April 23, 2024 |
Exhibit 10.1 19 April 2024 DB Capital Partners Healthcare, L.P. c/o Robert T. Dhamer DBC I, LLC 1165 Cypress Drive Brownsville, TX 78520 (the “Purchaser”) Re: Securities Purchase Agreement Dear Sirs and Madams: Reference is made to the securities purchase agreement between Renalytix plc (the “Company”) and the Purchaser dated 5 April 2024 (the “Securities Purchase Agreement”). The Purchaser has no |
|
| April 17, 2024 |
As filed with the Securities and Exchange Commission on April 17, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 17, 2024 Registration No. |
|
| April 17, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Renalytix plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity American Depositary Shares (ADSs) 457(c) 9,993,016 $0. |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| April 10, 2024 |
Renalytix plc (“Renalytix” or the “Company”) Issue of Shares Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Issue of Shares LONDON and SALT LAKE CITY – 10 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), announces the repayment of $1.06 million of principal and interest amount due under the Company’s convertible bonds for the period from 8 January 2024 to 7 April 2024, further details of the convertible bonds were announced on 31 March 2022 |
|
| April 9, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-274733 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 6, 2023) 2,666,667 Ordinary Shares We are offering 2,666,667 ordinary shares directly to an investor in this offering at a price per ordinary share of $0.375. This offering is being made without an underwriter or placement agent and we are not paying underwriting discou |
|
| April 9, 2024 |
Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 5, 2024 between Renalytix plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and each of the purchasers identified on Schedule A attached hereto (including such purchasers successors and assigns, each a “Purchaser” and, |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| April 8, 2024 |
Renalytix Announces Financing with Expected Size of up to $4 Million Exhibit 99.1 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECU |
|
| April 4, 2024 |
SC 13G 1 tm2411010d1sc13g.htm SC 13G CUSIP No: 75973T101 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Renalytix plc (Name of Issuer) Ordinary Shares, £0.0025 nominal value per share (Title of Class of |
|
| March 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| March 29, 2024 |
Exhibit 10.1 EXECUTION VERSION Dated 28 March 2024 Second Amendment and Restatement Agreement in respect of the Original Bond Agreement by Renalytix plc with CVI Investments, Inc. as Initial Bondholder White & Case llp 5 Old Broad Street London EC2N 1DW EMEA 149041286 Exhibit 10.1 White & Case llp 5 Old Broad Street London EC2N 1DW EMEA 149041286 Table of Contents 1. Definitions and Interpretation |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* RENALYTIX PLC (Name of Issuer) Ordinary Shares, nominal value £0.0025 per share Underlying American Depositary Shares (Title of Class of Securities) 75973T101 (American Depositary Shares) (CUSIP Number) Peter Trapani Chief Financial Officer Jefferson Riv |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| March 14, 2024 |
Exhibit 99.1 KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD) Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk LONDON and SALT LAKE CITY, March 14, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO (Kid |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| March 13, 2024 |
Exhibit 99.1 March 12, 2024 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN |
|
| March 13, 2024 |
Exhibit 10.1 Dated 12 March 2024 RENALYTIX PLC as the Company and STIFEL NICOLAUS EUROPE LIMITED as Bookrunner PLACING AGREEMENT in respect of a Placing to raise gross proceeds of approximately £7.8 million TABLE OF CONTENTS Page 1. Definitions and Interpretation 3 2. Conditions 10 3. Delivery of Documents 13 4. Applications for Admission 13 5. The Placing 14 6. Settlement 15 7. Undertakings 18 8. |
|
| March 13, 2024 |
Exhibit 99.2 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, |
|
| March 4, 2024 |
Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE “TAKEOVER CODE”) AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION |
|
| March 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| February 15, 2024 |
Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024 LONDON and SALT LAKE CITY, February 15, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for |
|
| February 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| February 14, 2024 |
Reference is made to Exhibit 3.1 Exhibit 3.1 RENALYTIX PLC ARTICLES OF ASSOCIATION ADOPTED ON 15 DECEMBER 2023 Contents Clause 1. Exclusion of model articles (and any other prescribed regulations) 1 2. Interpretation 1 3. Form of resolution 3 4. Limited liability 4 5. Change of name 4 6. Shareholder rights 4 7. Power to attach rights to shares 5 8. Allotment of shares and pre-emption 5 9. Redeemable shares 6 10. Pari passu issues |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39387 Renalyt |
|
| February 9, 2024 |
Exhibit 99.1 Renalytix plc ("Renalytix" or the "Company") Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for KidneyIntelX and kidneyintelX.dkd LONDON and SALT LAKE CITY, February 9, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on February 8, 2024 the Centers for Medicare and Medicaid Services (“CMS”) published a draft Local Coverage Determin |
|
| February 9, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| January 17, 2024 |
Exhibit 99.1 Renalytix plc ("Renalytix" or the "Company") Update on kidneyIntelX.dkd Local Coverage Determination Consideration Local Coverage Determination would result in contracted coverage for an estimated additional five million Medicare patients with Type 2 diabetes and early-stage chronic kidney disease LONDON and SALT LAKE CITY, January 17, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) a |
|
| January 17, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| January 10, 2024 |
Exhibit 99.1 New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months Results demonstrated a 61% increase in preventative drug prescriptions among patie |
|
| January 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| December 29, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| December 18, 2023 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| December 18, 2023 |
Renalytix plc (“Renalytix” or the “Company”) Issue of Shares Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Issue of Shares LONDON and SALT LAKE CITY – December 18, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), announces the repayment of $1.06 million of the Company’s convertible bond and the interest for the period, further details of which were announced on 31 March 2022. The repayment is being made through the issue of 2,500,000 Ordinary Sh |
|
| December 18, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| November 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2023 |
Exhibit 10.2 August 22, 2023 Howard Doran Dear Howard: Renalytix AI, Inc. ("Renalytix" or the "Company") is pleased to offer you the position of Chief Business Officer, reporting to James McCullough, Chief Executive Officer, with a dotted line to Tom Mclain, President. We feel strongly that your intellect, energy and experience are an ideal fit with our Company culture and objectives, and that you |
|
| November 14, 2023 |
Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024 LONDON and SALT LAKE CITY, November 14, 2023 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-b |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39387 Renaly |
|
| November 13, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| November 13, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| November 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| October 31, 2023 |
Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Announcement of AGM and Publication of Annual Report 2023 LONDON and SALT LAKE CITY, UT October 30, 2023 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Annual General Meeting (“AGM”) will be held in-person on 15 December 2023 at 15.30 p.m. (GMT) at 6 Stratton Street Mayfair, London W1J 8LD. In addition, the Company’s Annual R |
|
| October 31, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| October 17, 2023 |
Renalytix plc (“Renalytix” or the “Company”) Issue of Shares Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Issue of Shares LONDON and SALT LAKE CITY – October 17, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), announces the repayment of $1.06 million of the Company’s convertible bond, further details of which were announced on 31 March 2022. The repayment is being made through the issue of 150,000 Ordinary Shares and 1,092,694 American Deposit |
|
| October 17, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR c☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39387 |
|
| October 5, 2023 |
5-7 Cranwood Street London EC1V 9EE United Kingdom Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom October 5, 2023 VIA EDGAR U. |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| October 3, 2023 |
October 3, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Renalytix plc Registration Statement on Form S-3 (File No. 333-274733) Dear Sir or Madam: Pursuant to Rule 477 under the Securities Act of 1933, as amended, Renalytix plc (the “Company”) hereby requests withdrawal, effective immediately, of its Withdrawal Re |
|
| October 2, 2023 |
October 2, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 2, 2023 |
October 2, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 29, 2023 |
September 29, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 28, 2023 |
As filed with the Securities and Exchange Commission on September 28, 2023 Table of Contents As filed with the Securities and Exchange Commission on September 28, 2023 Registration No. |
|
| September 28, 2023 |
Form of Debt Securities Warrant Agreement and Warrant Certificate EX-4.6 Exhibit 4.6 RENALYTIX PLC and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF RENALYTIX PLC FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between RENALYTIX PLC, a public limited company incorporated under the laws of England and Wales under company number 11257655 and having its reg |
|
| September 28, 2023 |
EXHIBIT 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into effective June 1, 2019 (the “Effective Date”), by and among Thomas McLain (the “Employee”) and Renalytix AI, Inc. (“Renalytix DE” or the “Company”), a Delaware corporation, and Renalytix AI plc (“Parent” and collectively with Renalytix DE, the “Group”). The Company desires to continue to employ the Employ |
|
| September 28, 2023 |
Renalytix plc (“Renalytix” or the “Company”) Renalytix Reports Full Year Fiscal 2023 Results Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Renalytix Reports Full Year Fiscal 2023 Results LONDON and SALT LAKE CITY, September 28, 2023 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its fi |
|
| September 28, 2023 |
Form of Ordinary Share Warrant Agreement and Warrant Certificate. Exhibit 4.5 RENALYTIX PLC AND , AS WARRANT AGENT FORM OF ORDINARY SHARES WARRANT AGREEMENT DATED AS OF RENALYTIX PLC FORM OF ORDINARY SHARES WARRANT AGREEMENT THIS ORDINARY SHARES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between RENALYTIX PLC, a public limited company incorporated under the laws of England and Wales under company number 11257655 and having its registered office at Fi |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR c☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39387 Renalytix plc (Exa |
|
| September 28, 2023 |
EXHIBIT 10.9 Dated 2 NOVEMBER 2018 (1) RENALYTIX AI PLC (2) FERGUS FLEMING DIRECTORS SERVICE AGREEMENT Berry Smith Haywood House Dumfries Place Cardiff CF10 3GA THIS AGREEMENT is made the 2 day of November 2018 BETWEEN: (1) RENALYTIX AI PLC Registered Number 11257655 whose registered office is at Avon House, 19 Stanwell Road, Penarth, Cardiff CF64 2EZ (“the Company”); and (2) FERGUS FLEMING of 12 |
|
| September 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Renalytix plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value £0. |
|
| September 28, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| September 28, 2023 |
Subsidiaries of the registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction Renalytix AI, Inc. United States Renalytix AI Limited Ireland |
|
| September 28, 2023 |
EXHIBIT 10.16 EXECUTION VERSION DATED 30 OCTOBER 2018 RENALYTIX AI PLC and ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI and NPLUS1 SINGER ADVISORY LLP RELATIONSHIP AGREEMENT Cooley (UK) LLP DASHWOOD, 69 OLD BROAD STREET, LONDON EC2N 1QS, UK T: +44 (0) 20 7583 4055 f: +44 (0) 20 7785 9355 WWW.COOLEY.COM THIS AGREEMENT is made on 30 October 2018 BETWEEN: (1) RENALYTIX AI PLC, incorporated and registered |
|
| September 28, 2023 |
EXHIBIT 10.10 December 12, 2020 Michael J. Donovan PhD MD 601 NE 27th St., Apt. 1707 Miami, FL 33137 Dear Michael: Renalytix AI, Inc. (the “Company”) is pleased to offer you the position of Chief Medical Officer, reporting directly to CEO James McCullough. We feel strongly that your intellect, energy and experience are an ideal fit with our company culture and objectives, and that you would make a |
|
| September 28, 2023 |
As filed with the Securities and Exchange Commission on September 28, 2023 As filed with the Securities and Exchange Commission on September 28, 2023 Registration No. |
|
| September 28, 2023 |
EXHIBIT 10.6 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement’) is entered into on October 22, 2018 and shall become effective on the date of admission of the entire issued share capital of Renalytix AI plc (“Parent”) to trading on AIM, the market operated by London Stock Exchange plc (the “Effective Date”), by and among James McCullough (the “Employee”) and Renalytix AI, Inc. (“Rena |
|
| September 28, 2023 |
As filed with the Securities and Exchange Commission on September 28, 2023 Table of Contents As filed with the Securities and Exchange Commission on September 28, 2023 Registration No. |
|
| September 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) RENALYTIX PLC (Exact name of Registrant as specified in its charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value $0. |
|
| September 28, 2023 |
EXHIBIT 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into on October 12, 2018 and shall become effective on the date of admission of the entire issued share capital of Renalytix AI plc (“Parent”) to trading on AIM, the market operated by London Stock Exchange plc (the “Effective Date”), by and among Oliver James Sterling (the “Employee”) and Renalytix AI, Inc. ( |
|
| September 28, 2023 |
EX-4.3 Exhibit 4.3 Renalytix plc, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2. |
|
| September 28, 2023 |
As filed with the Securities and Exchange Commission on September 28, 2023 Table of Contents As filed with the Securities and Exchange Commission on September 28, 2023 Registration No. |
|
| September 22, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| September 8, 2023 |
Exhibit 99.1 Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort LONDON and SALT LAKE CITY – September 07, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individ |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| July 17, 2023 |
Exhibit 99.1 The following amendment has been made to the ‘Issue of Shares’ announcement released on 17 July 2023 at 07:00 under RNS No 1495G The correct figure for the principal remaining under the convertible bond after the settlement of the repayment is $15.90 million. All other details remain unchanged. The full amended text is shown below. Renalytix plc (“Renalytix” or the “Company”) Issue of |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| July 3, 2023 |
Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Directorate Change Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors LONDON and SALT LAKE CITY – July 3, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chroni |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2023 Renalytix plc (Exact name of registrant as specified in its Charter) England and Wales 001-39387 Not Applicable (State or other jurisdiction of incorporation) (Commission |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 30, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal ex |
|
| June 30, 2023 |
Exhibit 99.1 FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States Diabetic Kidney Disease is the Leading Cause of End Stage Kidney Disease in the United States LONDON and SA |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 9, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal exe |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 9, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal exe |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 22, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal exe |
|
| May 11, 2023 |
Finsgate, 5-7 Cranwood Street, London, EC1V 9EE Exhibit 99.1 11 May 2023 Dear Shareholder, Renalytix plc – Notice of General Meeting Please accept this letter as notification that a notice of general meeting (the “Notice of General Meeting”) has now been published on the Company’s website at https://investors.renalytix.com/news-and-events/documents-and-presentations and is enclosed for shareholders who elected for a hard copy of the Notice of G |
|
| May 11, 2023 |
Exhibit 99.2 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant, or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000, if you are resident in the United King |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 11, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal exe |
|
| May 11, 2023 |
Renalytix plc ("Renalytix" or the "Company") Notice of General Meeting and Posting of Circular Renalytix plc ("Renalytix" or the "Company") Notice of General Meeting and Posting of Circular LONDON and SALT LAKE CITY, May 11, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that a circular containing a notice convening a General Meeting to be held at the offices of Harwood Capital LLP, 6 Stratton Street Mayfair, London W1J 8LD at 3 p. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 11, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal exe |
|
| May 10, 2023 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-271579 PROSPECTUS 18,402,287 Ordinary Shares 3,379,237 Ordinary Shares 7,511,525 American Depositary Shares Representing 15,023,050 Ordinary Shares This prospectus relates to the resale by the selling securityholders identified in this prospectus, or the selling securityholders, of up to (i) 3,379,237 ordinary shares and |
|
| May 8, 2023 |
5-7 Cranwood Street London EC1V 9EE United Kingdom Acceleration Request Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom May 8, 2023 VIA EDGAR U. |
|
| May 2, 2023 |
Power of Attorney (included on signature page to registration statement) F-3 Table of Contents As filed with the Securities and Exchange Commission on May 2, 2023 Registration No. |
|
| May 2, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Renalytix plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity American Depositary Shares (ADSs) 457(c) 9,201,144 $2. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 30, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal e |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 27, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal e |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 21, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal e |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 10, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal e |
|
| February 17, 2023 |
SC 13D 1 tm237208d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* RENALYTIX PLC (Name of Issuer) Ordinary Shares, nominal value £0.0025 per share Underlying American Depositary Shares (Title of Class of Securities) 75973T101 (American Depositary Shares) (CUSIP Number) Peter Trapani |
|
| February 17, 2023 |
EX-99.1 2 tm237208d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on this Schedule 13D dated February 17, 2023 (including amendments thereto) with respect to the ordinary shares of Renalytix plc. Thi |
|
| February 17, 2023 |
RENALYTIX PLC Lock-Up Agreement February 7, 2023 EX-99.4 3 tm237208d1ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 RENALYTIX PLC Lock-Up Agreement February 7, 2023 Renalytix plc Finsgate 5-7 Cranwood Street London EC1V 9EE Re: Renalytix plc - Lock-Up Agreement Ladies and Gentlemen: The undersigned understands that Renalytix plc, a public limited company incorporated under the laws of England and Wales (the “Company”), is proposing to engage in a private |
|
| February 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 2)* Renalytix plc (Name of Issuer) Ordinary Shares, £0.0025 par value per share (Title of Class of Securities) 75973T101 (CUSIP Number) December 31, 2022 (Date of Event |
|
| February 10, 2023 |
EX-99.3 2 ex993.htm EXHIBIT 3 - RELATIONSHIP AGREEMENT EXECUTION VERSION DATED 30 OCTOBER 2018 RENALYTIX AI PLC and ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI and NPLUS1 SINGER ADVISORY LLP RELATIONSHIP AGREEMENT COOLEY (UK) LLP, DASHWOOD, 69 OLD BROAD STREET, LONDON EC2M 1QS, UK T: +44 (0) 20 7583 4055 F: +44 (0) 20 7785 9355 WWW.COOLEY.COM THIS AGREEMENT is dated 30 October 2018 BETWEEN: (1) RENALY |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* RENALYTIX PLC (Name of Issuer) ORDINARY SHARES (Including Ordinary Shares Underlying American Depository Shares) (Title of Class of Securities) 75973T101 (American Depository Shares) (CUSIP Number) Mount Sinai Health System, Inc. 150 East 42nd Street Suit |
|
| February 8, 2023 |
Execution Version Exhibit 99.4 REGISTRATION RIGHTS AGREEMENT by and between The Hamilton E. James 2003 Childrens Trust and Renalytix plc Dated as of February 6, 2023 Table of Contents Page 1. Certain Definitions. 1 2. Shelf Registration Statement. 3 3. Piggyback Registrations. 4 4. Other Registrations 5 5. Selection of Underwriters. 5 6. Procedures. 5 7. Registration Expenses. 9 8. Board Appointme |
|
| February 8, 2023 |
SECURITIES PURCHASE AGREEMENT (Ordinary Shares) Exhibit 99.2 Exhibit 99.2 SECURITIES PURCHASE AGREEMENT (Ordinary Shares) This Securities Purchase Agreement (this “Agreement”) is dated as of February 7, 2023 (the “Effective Date”), by and among Renalytix plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively |
|
| February 8, 2023 |
Renalytix plc ("Renalytix" or the "Company") Renalytix announces a c.$20.3 million private placement Exhibit 99.1 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING |
|
| February 8, 2023 |
SECURITIES PURCHASE AGREEMENT (American Depositary Shares) Exhibit 99.3 Exhibit 99.3 SECURITIES PURCHASE AGREEMENT (American Depositary Shares) This Securities Purchase Agreement (this “Agreement”) is dated as of February 7, 2023 (the “Effective Date”), by and among Renalytix plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and co |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 8, 2023 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 20, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant?s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principa |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 30, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant?s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principa |
|
| November 29, 2022 |
EX-99.1 2 rnlx-ex991.htm EX-99.1 Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared to low risk pat |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 29, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principa |
|
| November 22, 2022 |
Exhibit 99.3 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant, or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000, if you are resident in the United King |
|
| November 22, 2022 |
Finsgate, 5-7 Cranwood Street, London, EC1V 9EE Exhibit 99.2 10 November 2022 Dear Shareholder, Renalytix plc ? Annual Report 2022 and Notice of 2022 Annual General Meeting Please accept this letter as notification that Renalytix plc?s (the ?Company?) Annual Report for the year ended 30 June 2022 and the Notice of the 2022 Annual General Meeting have now been published on the Company?s website at https://investors.renalytix.com/news-and-events/ |
|
| November 22, 2022 |
On 30 June 2022 Ordinary Shares of 0.25p each Exhibit 99.1 Renalytix plc Annual Report and Financial Statements FOR THE YEAR ENDED 30 JUNE 2022 | Renalytix plc Annual Report and Financial Statements 1 Index STRATEGIC REPORT 3-21 Chairman & CEO?s Joint Statement 3 Company Overview 8 Operational and Financial Highlights 9 Product Overview and Strategy 11 Financial Review 13 Risk Management Approach 15 Section 172 Statement 19 Corporate Social R |
|
| November 22, 2022 |
6-K 1 rnlx-6-k-agmnotice.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 22, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE Un |
|
| November 22, 2022 |
EX-99.4 5 rnlx-ex994.htm EX-99.4 Exhibit 99.4 Annual General Meeting The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on December 13, 2022 for action to be taken. 2022 VOTING INSTRUCTIONS AMERICAN DEPOSITARY SHARES Renalytix plc (the “Company”) CUSIP No.: 75973T101. ADS Record Date: November 14, 2022. Meeting Specifics |
|
| October 31, 2022 |
EXHIBIT 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 |
|
| October 31, 2022 |
EXHIBIT 10.11 Dated 5 April 2022 Amendment and Restatement Agreement in respect of the Original Bond Agreement by Renalytix plc with CVI Investments, Inc. as Initial Bondholder White & Case LLP 5 Old Broad Street London EC2N 1DW CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT |
|
| October 31, 2022 |
Consent of Deloitte & Touche LLP, independent registered public accounting firm (PCAOB ID No. 34) Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement No. 333-265280 on Form F-3 and Registration Statement No. 333-248741 on Form S-8 of our report dated October 27, 2020, relating to the financial statements of Renalytix plc (formerly Renalytix AI plc) appearing in this Form 20-F for the year ended June 30, 20 |
|
| October 31, 2022 |
Consent of Ernst & Young LLP, independent registered public accounting firm (PCAOB ID No. 42) Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Post-Effective Amendment No.1 to the Registration Statement on Form F-3 (No. 333-265280) and to the Registration Statement on Form S-8 (No. 333-248741) pertaining to the Share Option Plan for Employees with Non-Employee Sub-Plan and U.S. Sub-Plan, 2020 Employee Share Purchase P |
|
| October 31, 2022 |
EXHIBIT 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, James McCullough, certify that: 1. I have reviewed this annual report on Form 20-F of Renalytix plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a m |
|
| October 31, 2022 |
EXHIBIT 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, O. James Sterling, certify that: 1. I have reviewed this annual report on Form 20-F of Renalytix plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a |
|
| October 31, 2022 |
Subsidiaries of the registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name Jurisdiction Renalytix AI, Inc. United States Renalytix AI Limited Ireland |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 13(d) OF THE SECURITIES EXCHANG |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 25, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal |
|
| October 25, 2022 |
Renalytix plc ("Renalytix" or the "Company") KidneyIntelX Medicare Update Exhibit 99.1 Renalytix plc ("Renalytix" or the "Company") KidneyIntelX Medicare Update NEW YORK and SALT LAKE CITY, October 25, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that, building on recently established private payer and Medicaid insurance coverage contracts for KidneyIntelX, the Federal Medicare Administrative Contractor (MAC) National Government Services (NGS) has ini |
|
| September 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 21, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant?s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of princip |
|
| September 21, 2022 |
Renalytix plc ("Renalytix" or the "Company") Renalytix Announces Change to Board of Directors Exhibit 99.1 Renalytix plc ("Renalytix" or the "Company") Renalytix Announces Change to Board of Directors LONDON and SALT LAKE CITY, 20 September 2022 ? Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Ann Berman, non-executive director and chair of the audit and nomination committees, has resigned as a director of the Company for personal reasons effective immediately. Ms. Berman commente |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: August 17, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant?s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal |
|
| August 1, 2022 |
EX-13.1 EXHIBIT 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States C |
|
| August 1, 2022 |
EX-12.2 EXHIBIT 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, O. James Sterling, certify that: 1. I have reviewed this annual report on Form 20-F of Renalytix plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to |
|
| August 1, 2022 |
Consent of Ernst & Young LLP, independent registered public accounting firm EX-15.1 5 d381344dex151.htm EX-15.1 EXHIBIT 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-248741) pertaining to the Share Option Plan for Employees with Non-Employee Sub-Plan and U.S. Sub-Plan, 2020 Employee Share Purchase Plan, and 2020 Equity Incentive Plan of Renalytix plc of our report |
|
| August 1, 2022 |
Consent of Deloitte & Touche LLP, independent registered public accounting firm EX-15.2 EXHIBIT 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement No. 333-248741 on Form S-8 of our report dated October 27, 2020, relating to the financial statements of Renalytix plc (formerly Renalytix AI plc) appearing in this Annual Report on Amendment No. 2 to Form 20-F/A for the years ended June 30, 2020 and |
|
| August 1, 2022 |
EX-12.1 EXHIBIT 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, James McCullough, certify that: 1. I have reviewed this annual report on Form 20-F of Renalytix plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to s |
|
| August 1, 2022 |
As filed with the Securities and Exchange Commission on August 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 1, 2022 Registration No. |
|
| August 1, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 2) (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 30, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant?s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Address of principal ex |
|
| June 27, 2022 |
Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30 Exhibit 99.1 Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30 NEW YORK and SALT LAKE CITY, June 23, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on Thursday, June 30, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the |
|
| June 27, 2022 |
6-K 1 rnlx-6-k-q3earningsannou.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 27, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE |
|
| June 6, 2022 |
424B3 1 d338565d424b3.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265280 PROSPECTUS 11,075,220 Ordinary Shares 1,052,197 American Depositary Shares Representing 13,179,614 Ordinary Shares This prospectus relates to the resale by the selling securityholders identified in this prospectus, or the selling securityholders, of (i) up to 11,075,220 ordinary shares an |
|
| June 2, 2022 |
5-7 Cranwood Street London EC1V 9EE United Kingdom CORRESP 1 filename1.htm Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom June 2, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Dorrie Yale Re: Renalytix plc Registration Statement on Form F-3 Filed May 27, 2022 File No. 333-265280 Acceleration Request Requested Date: June 6, 2022 Requested Time: |
|
| May 27, 2022 |
Exhibit 4.4 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 31, 2022 (the ?Effective Date?), by and among Renalytix plc, a public limited company incorporated under the laws of England and Wales (the ?Company?), and each purchaser identified on the signature pages hereto (each a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, the Co |
|
| May 27, 2022 |
As filed with the Securities and Exchange Commission on May 27, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 27, 2022 Registration No. |
|
| May 27, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Renalytix plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(6) Equity American Depositary Shares (ADSs) 457(c) 6,589,807 $3. |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Act of 1934 (Amendment No. 1)* RENALYTIX AI plc (Name of Issuer) ORDINARY SHARES (Including Ordinary Shares Underlying American Depository Shares) (Title of Class of Securities) 75973T101 (American Depository Shares) (CUSIP Number) March 31, 2022 (Date of Event Which Requires Filing of this St |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Act of 1934 (Amendment No. )* RENALYTIX AI plc (Name of Issuer) ORDINARY SHARES (Including Ordinary Shares Underlying American Depository Shares) (Title of Class of Securities) 75973T101 (American Depository Shares) (CUSIP Number) JULY 21, 2020 (Date of Event Which Requires Filing of this Stat |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 29, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kingdom (Addr |
|
| April 1, 2022 |
Renalytix plc ("Renalytix" or the "Company") Renalytix announces a $30.0 million financing package EX-99.1 2 rnlx-ex991.htm EX-99.1 Exhibit 99.1 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BU |
|
| April 1, 2022 |
6-K 1 rnlx-6-k-financing.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 1, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United |
|
| March 31, 2022 |
Exhibit 99.1 Renalytix plc (?Renalytix? or the ?Company?) Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022 LONDON and SALT LAKE CITY, March 31, 2022 ? Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-bas |
|
| March 31, 2022 |
6-K 1 rnlx-6-k-q3er.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 31, 2022 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kin |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 1)* Renalytix plc (Name of Issuer) Ordinary Shares, ?0.0025 par value per share (Title of Class of Securities) 75973T101 (CUSIP Number) December 31, 2021 (Date of Event |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 Renalytix plc (Name of Issuer) Ordinary Shares, £0.0025 par value per share (Title of Class of Securities) 75973T101 (CUSIP Number) December 31, 2020 (Date of Event which Requires Fili |
|
| January 27, 2022 |
EX-12.1 EXHIBIT 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, James McCullough, certify that: 1. I have reviewed this annual report on Form 20-F of Renalytix plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to s |
|
| January 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 13(d) OF TH |
|
| January 27, 2022 |
CORRESP 1 filename1.htm Marc Recht +1 617 937 2316 [email protected] VIA EDGAR January 27, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mary Mast Daniel Gordon Re: Renalytix plc Form 20-F for the fiscal year ended June 30, 2021 Filed October 21, 2021 File number 001-39387 Ladies and Gentlemen: This letter is submitted |
|
| January 27, 2022 |
EXHIBIT 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, O. James Sterling, certify that: 1. I have reviewed this annual report on Form 20-F of Renalytix plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a |
|
| December 20, 2021 |
6-K 1 d226133d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 20, 2021 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United Kin |
|
| December 7, 2021 |
EX-99.1 2 d259607dex991.htm EX-99.1 Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Renalytix Reports Financial Results for First Quarter of Fiscal Year 2022 LONDON and SALT LAKE CITY, December 7, 2021 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved p |
|
| December 7, 2021 |
6-K 1 d259607d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 7, 2021 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Finsgate 5-7 Cranwood Street London EC1V 9EE United King |
|
| November 30, 2021 |
6-K 1 d218032d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 30, 2021 Commission File Number: 001-39387 Renalytix plc (Translation of registrant’s name into English) Avon House 19 Stanwell Road Penarth, Cardiff CF64 2EZ U |
|
| November 30, 2021 |
EX-99.3 4 d218032dex993.htm EX-99.3 Exhibit 3 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document or the action you should take, you should immediately consult your stockbroker, bank manager, solicitor, accountant, or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000, if yo |
|
| November 30, 2021 |
EX-99.4 5 d218032dex994.htm EX-99.4 Exhibit 4 Annual General Meeting The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 A.M. (New York City time) on December 13, 2021 for action to be taken. 2021 VOTING INSTRUCTIONS AMERICAN DEPOSITARY SHARES Renalytix plc (the “Company”) CUSIP No.: 75973T101. ADS Record Date: November 22, 2021. Meeting Specifics |
|
| November 30, 2021 |
Finsgate, 5-7 Cranwood Street, London, EC1V 9EE Exhibit 2 19 November 2021 Dear Shareholder, Renalytix plc ? Annual Report 2021 and Notice of 2021 Annual General Meeting Please accept this letter as notification that Renalytix plc?s (the ?Company?) Annual Report for the year ended 30 June 2021 and the Notice of the 2021 Annual General Meeting have now been published on the Company?s website at https://investors. |
|
| November 30, 2021 |
REMUNERATION COMMITTEE REPORT DR. ERIK LIUM CHAIR OF THE REMUNERATION EX-99.1 2 d218032dex991.htm EX-99.1 Exhibit 1 Renalytix plc Annual Report and Financial Statements FOR THE YEAR ENDED 30 JUNE 2021 | Renalytix plc Annual Report and Financial Statements 2 Index STRATEGIC REPORT 4-23 Chairman & CEO’s Joint Statement 4 Company Overview 9 Operational and Financial Highlights 10 Product Overview and Strategy 12 Financial Review 15 Risk Management Approach 17 Section 1 |
|
| October 21, 2021 |
Renalytix plc (“Renalytix” or the “Company”) Renalytix Reports Full Year Fiscal 2021 Results EX-99.1 2 d164692dex991.htm EX-99.1 Exhibit 99.1 Renalytix plc (“Renalytix” or the “Company”) Renalytix Reports Full Year Fiscal 2021 Results LONDON and SALT LAKE CITY, October 21, 2021 – Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advanc |
|
| October 21, 2021 |
EX-12.1 EXHIBIT 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, James McCullough, certify that: 1. I have reviewed this annual report on Form 20-F of Renalytix plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to s |
|
| October 21, 2021 |
EXHIBIT 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 |
